<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the year 1992, 203 teams in 26 countries in Europe performed a total of 6065 bone marrow transplantations (BMT) </plain></SENT>
<SENT sid="1" pm="."><plain>Transplant source in 2666 cases (44%) was an allogeneic donor, in 2171 cases an HLA-identical sibling donor, in 170 a non-identical family donor, in 29 a twin donor and in 296 cases an unrelated volunteer donor </plain></SENT>
<SENT sid="2" pm="."><plain>There were 3399 autologous transplants (56%): 2494 autologous BMT, 644 autologous peripheral blood stem cell transplants and 261 combined autologous BM and peripheral blood stem cell transplants </plain></SENT>
<SENT sid="3" pm="."><plain>Indications for transplant were <z:hpo ids='HP_0001909'>leukemias</z:hpo> in 2963 patients (49%; 1987 allogeneic, 976 autologous), <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> in 1890 patients (31%; 201 allogeneic, 1689 autologous), <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> in 739 patients (12%; 10 allogeneic, 739 autologous), <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in 194 patients (3%; 193 allogeneic, 1 autologous), <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> in 128 patients (2%; allogeneic), inborn errors in 115 patients (2%; allogeneic) and miscellaneous disorders in 36 patients (32 allogeneic, 4 autologous) </plain></SENT>
<SENT sid="4" pm="."><plain>Compared with an EBMT survey 2 years ago, there was an increase in the number of participating institutions and in the number of transplants performed from <z:hpo ids='HP_0000001'>all</z:hpo> sources </plain></SENT>
<SENT sid="5" pm="."><plain>If the 142 teams reporting in 1990 and 1992 are compared alone, there is an increase in unrelated allogeneic BMT and in autologous BMT </plain></SENT>
<SENT sid="6" pm="."><plain>There was an increase in autologous transplants for <z:mp ids='MP_0009440'>myeloma</z:mp> and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>These data confirm a continuing trend to apply BMT as a therapeutic modality </plain></SENT>
</text></document>